Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. (linkinghub.elsevier.com)

Authors: Bourhis J … Tao Y Journal: The Lancet Published: 2026-01-24 DOI: https://doi.org/10.1016/S0140-6736(25)01850-1